DHR - Danaher Corporation
Barron's Oil & Blue Chip Tips for May 2026 highlight 20 stocks, with 11 deemed 'safer' based on free cash flow yields exceeding dividend yields. Top ten by yield are projected to deliver average net gains of 36.08% by May 2027, with risk/volatility 24% below the market average. Zoetis (ZTS), Danaher (DHR), and Accenture (ACN) lead in projected returns, with ZTS estimated to net 60.33% and lower-than-market volatility.
Danaher (DHR) reported earnings 30 days ago. What's next for the stock?
DHR's Biotechnology segment posts 7% core revenue growth as bioprocessing demand stayed strong and equipment orders jumped despite headwinds.
Pre-Market Stock Futures: Futures are trading sharply lower as we get set to end one of the most exciting weeks on Wall Street in 25 years. Positive meetings in China with President Trump, who brought his CEO contingent and Elon Musk, and President Xi, massive upside earnings and forward guidance from an OG tech and... Here Are Friday's Top Wall Street Analyst Research Calls: Arista Networks, BWX Technologies, Cisco Systems, Danaher, Doximity, Estee Lauder, Illumina, Texas Roadhouse, Workday, and More
Danaher Corporation (DHR) Presents at Bank of America Global Healthcare Conference 2026 Transcript
WASHINGTON, May 6, 2026 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) announced that President and Chief Executive Officer, Rainer M. Blair, will be presenting at the Bank of America Securities Health Care Conference in Las Vegas, Nevada on Wednesday, May 13, 2026 at 11:20 a.m.
WASHINGTON, May 5, 2026 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) announced today that its Board of Directors has approved a regular quarterly cash dividend of $0.40 per share of its common stock, payable on July 31, 2026 to holders of record on June 26, 2026. ABOUT DANAHER Danaher is a leading global life sciences and diagnostics innovator, committed to accelerating the power of science and technology to improve human health.
IRVINE, Calif.--(BUSINESS WIRE)--Masimo Corporation (Nasdaq: MASI) (“Masimo”), a leading global innovator in patient monitoring, today announced that its stockholders voted in favor of the proposal to adopt the previously announced Agreement and Plan of Merger, dated February 16, 2026 (the “Merger Agreement”), by and among Masimo, Danaher Corporation (“Danaher”) (NYSE: DHR) and Mobius Merger Sub, Inc. (the “Merger Sub”) at Masimo's special meeting of stockholders held virtually on May 1, 2026 (.
XYL tops Q1 estimates as Measurement & Control demand lifts results, while raising 2026 revenue outlook.
AEGON ASSET MANAGEMENT UK Plc lifted its stake in shares of Danaher Corporation (NYSE: DHR) by 81.1% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 328,147 shares of the conglomerate's stock after purchasing an additional 146,929 shares during the quarter. Danaher comprises
Calamos Advisors LLC boosted its holdings in Danaher Corporation (NYSE: DHR) by 9.0% in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 243,698 shares of the conglomerate's stock after purchasing an additional 20,180 shares during the quarter. Calamos Advisors LLC's
This blue chip stock has been in a multiyear slump, but things are looking up.
Arizona State Retirement System decreased its position in shares of Danaher Corporation (NYSE: DHR) by 3.6% during the undefined quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 181,341 shares of the conglomerate's stock after selling 6,790 shares during the period. Arizona State Retirement System's
Danaher reached a $172.5 million settlement with shareholders who accused the diagnostics and life-sciences company of defrauding them by overstating demand for its equipment as the worst of the COVID-19 pandemic passed.
WASHINGTON, April 22, 2026 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) ("Danaher") announced today that it has priced an offering of the following euro-denominated senior notes (the "Offering"): €500,000,000 principal amount of floating rate senior notes due 2028 at an offering price of 100.000% of the principal amount; €750,000,000 principal amount of 3.250% senior notes due 2030 at an offering price of 99.934% of the principal amount; €750,000,000 principal amount of 3.625% senior notes due 2034 at an offering price of 99.918% of the principal amount; and €1,000,000,000 principal amount of 4.000% senior notes due 2038 at an offering price of 99.953% of the principal amount (collectively, the "senior notes"). Danaher estimates that the net proceeds from the sale of the senior notes will be approximately €2.98 billion, after deducting the underwriting discounts and estimated offering expenses payable by Danaher.
Danaher had another somewhat uneventful quarter. Margin in biotechnology segment improved YoY to reach 42.7% in 1Q'26. Life Sciences segment's core revenue grew at only 0.5% despite having an easy comp of -4% in 1Q'25.
Danaher (NYSE: DHR) reported first-quarter 2026 sales of $6.0 billion, with core revenue up 0.5% year over year as strength in bioprocessing and better-than-expected life sciences performance largely offset a lighter-than-normal respiratory season at Cepheid. President and CEO Rainer Blair said the company delivered "better than expected adjusted EPS growth" by "leveraging the Danaher Business System
DHR beats Q1 EPS estimates and lifts 2026 outlook, but revenues miss as Diagnostics lags while bioprocessing strength and Masimo deal shape growth plans.
Investors interested in Medical Services stocks are likely familiar with Labcorp Holdings (LH) and Danaher (DHR). But which of these two stocks is more attractive to value investors?
Danaher Corp (NYSE:DHR) on Tuesday reported first-quarter 2026 sales of $5.95 billion, up 3.5% year-over-year, but under the consensus of $5.99 billion. Core revenue increased 0.5% year-over-year.